This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC.

We would like to rely on WCG IRB as the local IRB of record for this study.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: - 99 Years
• Gender: All